Project Grant R01DK149584
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Research Foundation For The State University Of New York $799,752 on July 1, 2026, to conduct a randomized controlled trial comparing the efficacy of continuous glucose monitoring relative to traditional finger-stick self-monitoring of blood glucose in non-insulin-treated adults with poorly controlled type 2 diabetes. The study randomizes approximately 240 participants (≥8% of whom identify as African American) in a...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Research Foundation For The State University Of New York $800,434 on August 24, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a conditional cash transfer and basic needs resolution intervention for low-income adults with Type 2 Diabetes. The award funds research addressing the disproportionate burden of Type 2 Diabetes among individuals living below 133...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham & Women's Hospital $891,382 on May 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a multisite evaluation of continuous glucose monitoring (CGM) effectiveness in older adults with type 2 diabetes. The recipient will assess how CGM-derived metrics influence clinician behavior and therapeutic decision-making, compare clinical outcomes and care...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Houston $784,276 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate the impact of continuous glucose monitors (CGMs) on prediabetes management in Federally Qualified Health Center (FQHC) populations through a five-year project concluding June 30, 2031. The research, titled SMART Prediabetes (Supporting Monitoring and Remote Tracking...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $1.638 million on September 11, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research using continuous glucose monitoring systems and machine learning methods to identify glucose pattern clusters and high-risk subgroups in persons with and without diabetes. The project, titled "Glucose Patterns and Clinical Outcomes in the...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded New York University $1.94 million on September 19, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate an adaptive dietary intervention leveraging continuous glucose monitoring for Asian Americans with type 2 diabetes. The project will assess the feasibility, acceptability, and effect of an adaptive dietary intervention integrating continuous glucose...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $755,834 under Project Grant R01DK149276 on August 15, 2026, to evaluate an integrated multimodal digital health platform for type 2 diabetes management. The award funds a three-arm randomized controlled trial enrolling 300 adults with type 2 diabetes to assess a unified digital health intervention that synchronizes continuous glucose monitoring data, wearable device outputs (sleep and physical...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Scripps Health $331,277 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research integrating continuous glucose monitoring (CGM) in diabetes self-management education and support to improve glycemic control in Latino adults with type 2 diabetes. The research, titled "Integrating Continuous Glucose Monitoring in Diabetes Self-Management...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Healthpartners Institute $314,000 on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and test RISE-CGM (Real-Time Insights for Smart Engagement with CGM), a digital behavior change intervention targeting type 2 diabetes self-management. RISE-CGM is a 28-week scalable intervention (16 weeks active, 12 weeks maintenance) that delivers evidence-based...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Kaiser Foundation Hospitals $370,000 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify evidence-based target thresholds for continuous glucose monitoring metrics in adults with type 1 diabetes. The recipient will use causal machine learning models to establish optimal targets for eight standard CGM metrics (including time in range, defined as...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Research Foundation For The State University Of New York $798,814 on August 1, 2026, for a randomized controlled trial testing continuous glucose monitoring combined with health coaching and values clarification in older adults with poorly controlled type 2 diabetes. The intervention targets 300 participants aged 65 and older with hemoglobin A1c of 9 percent or higher, randomized 1:1 to the intervention or standard care. The trial evaluates three outcome domains: patient-centered outcomes including activation, shared decision-making, and satisfaction; quality of life and physical, mental, and social functioning; and health care utilization and geriatric syndromes including frailty, functional decline, cognitive decline, and falls. The intervention pairs real-time glucose data from continuous glucose monitoring with weekly remote health coaching structured around values clarification to empower participants to interpret glucose patterns and engage clinicians in values-concordant decision-making. The award is a Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Performance occurs in Buffalo, New York, with a period of performance from August 1, 2026, through June 30, 2031. RF SUNY receives the award as the fiscal and administrative agent for the State University of New York system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $798.8k | 7/20/26 |